首页> 外文期刊>European review for medical and pharmacological sciences. >MiRNA-206 inhibits proliferation of renal clear cell carcinoma by targeting ZEB2
【24h】

MiRNA-206 inhibits proliferation of renal clear cell carcinoma by targeting ZEB2

机译:MiRNA-206通过靶向Zeb2抑制肾透明细胞癌的增殖

获取原文
       

摘要

OBJECTIVE: The purpose of this study was to investigate the effect of microRNA-206 on the malignant progression of renal clear cell carcinoma (RCC). In addition, whether microRNA-206 could regulate ZEB2 expression and the underlying mechanisms was also explored. PATIENTS AND METHODS: Quantitative Real Time-Polymerase Chain Reaction (qRT-PCR) was performed to examine microRNA-206 level in 46 tumor tissue specimens and adjacent ones of RCC patients. Also, the relationship between microRNA-206 expression and clinical indicators of RCC was analyzed. The negative control (NC) and microRNA-206 mimics were transfected into RCC cell lines, and the transfection efficiency was verified by qRT-PCR. The effects of microRNA-206 on the proliferation and apoptosis of RCC cells were analyzed by cell counting kit-8 (CCK-8), clone formation, and flow cytometry assays. Finally, the regulation of microRNA-206 on the downstream gene ZEB2 was indicated by Western Blot and cell recovery experiments. RESULTS: qRT-PCR results showed that the expression level of microRNA-206 in tumor tissue samples of RCC patients was remarkably lower than that in adjacent normal tissues, and the difference was statistically significant. Meanwhile, compared with patients with high expression of microRNA-206, the pathological stage of patients with low expression of microRNA-206 was higher, and the overall survival rate was lower. In the RCC cell lines (Caki-1 and Caki-2), the cell proliferation ability of the microRNA-206 overexpression group was remarkably weakened, while the cell apoptosis rate was oppositely enhanced when compared with the NC group. In addition, this study demonstrated that ZEB2 expression was remarkably increased in RCC cells as well as tissues and was negatively correlated with microRNA-206 expression. At the same time, microRNA-206 mimics was found remarkably reduced in the expression of proteins in ZEB2-related signaling pathway, including ZEB2, β-catenin, cyclinD1, c-Myc, MMP-2, and MMP-9. In the cell reverse experiment, the overexpression of ZEB2 was found to be able to counteract the impact of microRNA-206 mimics on RCC cell proliferation and apoptosis and thus, participated in the malignant progression of RCC. CONCLUSIONS: This study revealed that microRNA-206 was remarkably associated with the pathological stage and poor prognosis of RCC patients. In addition, microRNA-206 might inhibit the malignant progression of RCC by regulating the targeted ZEB2.
机译:目的:本研究的目的是探讨MicroRNA-206对肾透明细胞癌(RCC)恶性进展的影响。此外,MicroRNA-206是否可以调节Zeb2表达,并且还探讨了潜在机制。患者和方法:进行定量实时聚合酶链反应(QRT-PCR),以检查46个肿瘤组织标本和邻近RCC患者的MicroRNA-206水平。此外,分析了MicroRNA-206的关系与RCC的表达和临床指标的关系。将阴性对照(NC)和MicroRNA-206模拟物转染到RCC细胞系中,通过QRT-PCR验证转染效率。通过细胞计数试剂盒-8(CCK-8),克隆形成和流式细胞术测定分析MicroRNA-206对RCC细胞增殖和凋亡的影响。最后,通过蛋白质印迹和细胞回收实验表明了下游基因Zeb2上的MicroRNA-206的调节。结果:QRT-PCR结果表明,RCC患者肿瘤组织样品中MicroRNA-206的表达水平显着低于相邻的正常组织中的表达水平,差异有统计学意义。同时,与MicroRNA-206的高表达患者相比,MicroRNA-206表达低表达的病理阶段更高,总存活率较低。在RCC细胞系(CAKI-1和CAKI-2)中,微小RORNA-206过表达组的细胞增殖能力显着削弱,而与NC组相比,细胞凋亡率与细胞凋亡率相反。此外,该研究表明,在RCC细胞以及组织中,ZeB2表达显着增加,并且与MicroRNA-206表达呈负相关。同时,在Zeb2相关信号通路中的蛋白质表达中发现MicroRNA-206模拟物显着降低,包括ZeB2,β-Catenin,CyclinD1,C-Myc,MMP-2和MMP-9。在细胞反向实验中,发现Zeb2的过表达能够抵消MicroRNA-206模拟对RCC细胞增殖和细胞凋亡的影响,从而参与RCC的恶性进展。结论:本研究表明,MicroRNA-206与病理阶段显着相关,RCC患者的预后不良。此外,MicroRNA-206可以通过调节靶向Zeb2来抑制RCC的恶性进展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号